Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma

被引：12

作者：

Okada, Takuro ^{[1
]}

Okamoto, Isaku ^{[1
]}

Sato, Hiroki ^{[1
]}

Ito, Tatsuya ^{[1
]}

Miyake, Keitaro ^{[1
]}

Tsukahara, Kiyoaki ^{[1
]}

机构：

[1] Tokyo Med Univ, Dept Otorhinolaryngol & Head & Neck Surg, Tokyo, Japan

来源：

IN VIVO | 2021年 / 35卷 / 02期

关键词：

Paclitaxel; cetuximab; head and neck; squamous cell carcinoma; PLATINUM-BASED CHEMOTHERAPY; PLUS CETUXIMAB; RECURRENT; NIVOLUMAB;

D O I：

10.21873/invivo.12376

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background/Aim: For recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), popular regimens containing platinum-based anticancer agents and immune checkpoint inhibitors are impractical for platinum-intolerant patients. Herein, the efficacy and safety of paclitaxel and cetuximab combination therapy in R/M SCCHN were evaluated. Patients and Methods: In this retrospective study, paclitaxel (80 mg/m(2)) and cetuximab (400 mg/m(2) loading dose followed by 250 mg/m(2) weekly) were administered in 28-day cycles on days 1, 8, and 15. Results: Thirty-eight patients were treated. The overall response and disease control rates of first-line therapy were 43% and 79%, respectively, while those of second-line and later therapies were 20% and 90%, respectively. The median progression-free and overall survival were 5.3 and 125 months, respectively. All adverse events were manageable, including grade 3/4 neutropenia and anaemia affecting 8-13% of patients. Conclusion: Paclitaxel and cetuximab combination therapy may be suitable for treating R/M SCCHN.

引用

页码：1253 / 1259

页数：7

共 24 条

[1]

[Anonymous], 2010, Common Terminology Criteria for Adverse Events (CTCAE)

[2]

[Anonymous], NCCN CLIN PRACTICE G

[3]

Bristol-Myers Squibb, DRUG INF SHEET PACL

[4] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[5] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[6] Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck [J].

Enokida, Tomohiro ;

Okano, Susumu ;

Fujisawa, Takao ;

Ueda, Yuri ;

Uozumi, Shinya ;

Tahara, Makoto .

FRONTIERS IN ONCOLOGY, 2018, 8

[7] Predictors of Outcome With Cetuximab and Paclitaxel for Head and Neck Squamous Cell Carcinoma [J].

Ferreira, Bruna Pellini ;

Redman, Mary ;

Baker, Kelsey K. ;

Martins, Renato ;

Eaton, Keith D. ;

Chow, Laura Quan Man ;

Baik, Christina S. ;

Goulart, Bernardo ;

Lee, Sylvia Mina ;

Santana-Davila, Rafael ;

Rodriguez, Cristina P. .

LARYNGOSCOPE, 2017, 127 (07) :1583-1588

[8] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].

Ferris, R. L. ;

Blumenschein, G., Jr. ;

Fayette, J. ;

Guigay, J. ;

Colevas, A. D. ;

Licitra, L. ;

Harrington, K. ;

Kasper, S. ;

Vokes, E. E. ;

Even, C. ;

Worden, F. ;

Saba, N. F. ;

Iglesias Docampo, L. C. ;

Haddad, R. ;

Rordorf, T. ;

Kiyota, N. ;

Tahara, M. ;

Monga, M. ;

Lynch, M. ;

Geese, W. J. ;

Kopit, J. ;

Shaw, J. W. ;

Gillison, M. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867

[9] Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma [J].

Fushimi, Chihiro ;

Okamoto, Isaku ;

Matsuki, Takashi ;

Masubuchi, Tatsuo ;

Okada, Takuro ;

Sato, Hiroki ;

Tsukahara, Kiyoaki ;

Kondo, Takahito ;

Yamashita, Taku ;

Hanyu, Kenji ;

Omura, Go ;

Takahashi, Hideaki ;

Tada, Yuichiro ;

Miura, Kouki .

ANTICANCER RESEARCH, 2020, 40 (09) :5277-5283

[10] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck [J].

Hitt, R. ;

Irigoyen, A. ;

Cortes-Funes, H. ;

Grau, J. J. ;

Garcia-Saenz, J. A. ;

Cruz-Hernandez, J. J. .

ANNALS OF ONCOLOGY, 2012, 23 (04) :1016-1022

← 1 2 3 →